Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Affiliation auteurs!!!! Error affiliation !!!!
TitreResults of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER
Type de publicationJournal Article
Year of Publication2020
AuteursDuffaud F., Blay J-Y., Mir O., Chevreau C.M, P. Rouquette B, Kalbacher E., Penel N., Perrin C., Laurence V., Bompas E., Saada-Bouzid E., Delcambre C., Bertucci F., Cancel M., Schiffler C., Monard L., Bouvier C., Vidal V., Gaspar N., Chabaud S.
JournalANNALS OF ONCOLOGY
Volume31
PaginationS1199
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2020.08.2309